Gene | CHR | SNP | BP | Allele† | Genetic main effect | Interaction with RSV infection in TCCAS | ||||||||||
TCCAS* | CAMP | Combined p value | FDR | |||||||||||||
MAF† | OR | L95 | U95 | P value | OR | L95 | U95 | P value | FDR | |||||||
Additive genetic model | ||||||||||||||||
GADD45A | 1 | rs520820 | 68 148 353 | T/C | 0.44 | 1.46 | 1.11 | 1.93 | 7.24E-03 | 1.03 | 0.82 | 1.30 | 8.04E-01 | 3.58E-02 | 3.58E-02 | 0.97 |
GYPB | 4 | rs55915952 | 144 890 200 | C/T | 0.46 | 1.46 | 1.10 | 1.93 | 8.36E-03 | 1.75 | 0.99 | 3.07 | 5.37E-02 | 3.91E-03 | 5.40E-03 | 0.90 |
MS4A3 | 11 | rs479240 | 59 830 370 | T/G | 0.35 | 1.68 | 1.27 | 2.24 | 3.39E-04 | 1.04 | 0.85 | 1.28 | 6.80E-01 | 2.16E-03 | 5.40E-03 | 0.99 |
NFE2 | 12 | rs73114552 | 54 710 793 | T/C | 0.18 | 1.74 | 1.21 | 2.50 | 2.65E-03 | 1.24 | 0.89 | 1.71 | 2.05E-01 | 4.61E-03 | 5.40E-03 | 0.20 |
EPB41L3 | 18 | rs77751403 | 5 480 030 | C/T | 0.05 | 2.90 | 1.49 | 5.63 | 1.67E-03 | 1.35 | 0.81 | 2.24 | 2.45E-01 | 3.60E-03 | 5.40E-03 | 0.57 |
CEACAM6 | 19 | rs8106277 | 42 267 724 | T/C | 0.37 | 1.54 | 1.14 | 2.08 | 4.95E-03 | 1.19 | 0.96 | 1.47 | 1.05E-01 | 4.46E-03 | 5.40E-03 | 0.74 |
CEACAM3 | 19 | rs7251960 | 42 306 043 | T/C | 0.40 | 1.71 | 1.28 | 2.30 | 3.53E-04 | 1.19 | 0.96 | 1.47 | 1.19E-01 | 4.60E-04 | 3.20E-03 | 0.05 |
Dominant genetic model | ||||||||||||||||
MS4A3 | 11 | rs1286276 | 59 817 661 | A/G | 0.22 | 2.06 | 1.37 | 3.09 | 4.88E-04 | 1.20 | 0.89 | 1.61 | 2.39E-01 | 1.17E-03 | 5.28E-03 | 0.75 |
MS4A3 | 11 | rs479240 | 59 830 370 | T/G | 0.35 | 1.86 | 1.24 | 2.78 | 2.67E-03 | 1.12 | 0.82 | 1.51 | 4.75E-01 | 9.71E-03 | 1.46E-02 | 0.99 |
NFE2 | 12 | rs73114552 | 54 710 793 | T/C | 0.18 | 1.97 | 1.30 | 2.99 | 1.39E-03 | 1.12 | 0.79 | 1.59 | 5.28E-01 | 6.01E-03 | 1.08E-02 | 0.08 |
RNASE3 | 14 | rs11156741 | 21 356 925 | C/G | 0.17 | 1.93 | 1.28 | 2.91 | 1.82E-03 | 1.03 | 0.77 | 1.37 | 8.62E-01 | 1.17E-02 | 1.51E-02 | 0.28 |
EPB41L3 | 18 | rs77751403 | 5 480 030 | C/T | 0.05 | 2.91 | 1.48 | 5.72 | 2.01E-03 | 1.30 | 0.77 | 2.19 | 3.32E-01 | 5.53E-03 | 1.08E-02 | 0.31 |
EPB41L3 | 18 | rs7243561 | 5 631 947 | C/T | 0.37 | 1.79 | 1.19 | 2.70 | 5.33E-03 | 1.16 | 0.34 | 3.98 | 8.09E-01 | 2.78E-02 | 3.13E-02 | 0.36 |
EPB41L3 | 18 | rs12172862 | 5 635 388 | T/C | 0.33 | 1.65 | 1.11 | 2.47 | 1.41E-02 | 1.23 | 0.71 | 2.14 | 4.59E-01 | 3.91E-02 | 3.91E-02 | 0.81 |
CEACAM6 | 19 | rs8106277 | 42 267 724 | T/C | 0.37 | 1.75 | 1.15 | 2.65 | 8.72E-03 | 1.42 | 0.98 | 2.05 | 6.48E-02 | 4.79E-03 | 1.08E-02 | 0.42 |
CEACAM3 | 19 | rs7251960 | 42 306 043 | T/C | 0.40 | 2.58 | 1.65 | 4.03 | 3.12E-05 | 1.54 | 1.03 | 2.31 | 3.50E-02 | 1.61E-05 | 1.40E-04 | 0.03 |
Models adjusted by age, sex, medication use, BMI, PC1-PC2 in TCCAS.
Models adjusted by age, sex, race, treatment groups, BMI, PC1-PC10 in CAMP.
*After SNPs filtering by gene-based analysis, original (SNP-based) ORs and p values were showed in TCCAS columns.
†Effect allele/referent allele; MAF on TCCAS cohort.
BMI, body mass index; BP, base pair; CAMP, Childhood Asthma Management Program; CHR, chromosome; FDR, false-discovery rate; L95, lower 95% CI of OR; MAF, minor allele frequency on TCCAS cohort; RSV, respiratory syncytial virus; TCCAS, Taiwanese Consortium of Childhood Asthma Study; U95, upper 95% CI of OR.